Accidental death involving psilocin from ingesting “magic mushroom”

Garg, Uttam; Knoblauch, Jeff; Frazee, C. Clinton; Baron, Adrian; Dudley, Mary H.

doi:10.1016/b978-0-12-815846-3.00077-6

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some cases of fatal intoxication have been reported; however, the majority of them were not directly linked to the toxic effects induced by psilocybin. They were related to mixed drug intoxication, suicide, and jumping out of the window during hallucinations [ 26 , 63 ]. In 1996, Gerault and Picart described a case in which a massive dose of psilocybe semilanceata was considered as the cause of death.…”

Section: Toxicitymentioning

confidence: 99%

Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Coppola

Bevione

Mondola

2022

JoX

View full text Add to dashboard Cite

Psychedelics extracted from plants have been used in religious, spiritual, and mystic practices for millennia. In 1957, Dr. Hofmann identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although there were limitations related to the scientific design of many studies, clinical observations performed during the 1950s and 1960s showed a potential therapeutic effect of psilocybin for patients affected by depressive symptoms, anxiety, and conversion disorder. Psilocybin was classed as a schedule I substance in 1970, but the fascination with psychedelics has remained almost unchanged over time, promoting a new scientific interest starting in the 1990s. Recent studies have provided further evidence supporting the suggestive hypothesis of the therapeutic use of psilocybin for treating various psychiatric disorders, including pathological anxiety, mood depressive disorder, and addiction.

show abstract

Section: Toxicitymentioning

confidence: 99%

Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Coppola

Bevione

Mondola

2022

JoX

View full text Add to dashboard Cite

show abstract

“…The species of the genera Conocybe, Gymnopilus, Panaeolus, Pluteus, Psilocybe, and St pharia have been reported to be hallucinogenic mushrooms that contain psilocybin [47,4 Among the species of the genus Stropharia, S. coronilla has been reported to produ psilocin/psilocybin [49], and no psilocin/psilocybin was detected in S. rugosoannulata high-performance liquid chromatography (HPLC) analysis [50]. Enzymatic synthesis psilocybin has been reported in the phylogenetically closed species P. cubensis and P. c nescens [29].…”

Section: No Genes Encoding Psilocybin Biosynthesis Enzymes Were Predi...mentioning

confidence: 99%

Genomic Analysis of Stropharia rugosoannulata Reveals Its Nutritional Strategy and Application Potential in Bioremediation

Yang

Meng

et al. 2022

JoF

View full text Add to dashboard Cite

Stropharia rugosoannulata is not only a popular edible mushroom, but also has excellent potential in bioremediation. In this study, we present a high-quality genome of a monokaryotic strain of the S. rugosoannulata commercial cultivar in China. The assembly yielded an N50 length of 2.96 Mb and a total size of approximately 48.33 Mb, encoding 11,750 proteins. The number of heme peroxidase-encoding genes in the genome of S. rugosoannulata was twice the average of all of the tested Agaricales. The genes encoding lignin and xenobiotic degradation enzymes accounted for more than half of the genes encoding plant cell wall degradation enzymes. The expansion of genes encoding lignin and xenobiotic degradation enzymes, and cytochrome P450 involved in the xenobiotic metabolism, were responsible for its strong bioremediation and lignin degradation abilities. S. rugosoannulata was classified as a litter-decomposing (LD) fungus, based on the analysis of the cell wall degrading enzymes. Substrate selection for fruiting body cultivation should consider both the nutritional strategy of LD and a strong lignin degradation ability. Consistent with safe usage as an edible mushroom, the S. rugosoannulata genome does not contain genes for known psilocybin biosynthesis. Genome analysis will be helpful for understanding its nutritional strategy to guide fruiting body cultivation and for providing insight into its application in bioremediation.

show abstract

“…Some cases of fatal intoxication have been anyway reported, however, the majority of them were not directly linked to the toxic effects induced by psilocybin. They were generally related to a mixed drug intoxication, suicide, and jumping out of the window [26,62]. In 1996, it was described a case in which a massive dose of psilocybe semilanceata was considered as cause of death.…”

Section: Toxicitymentioning

confidence: 99%

Psilocybin for Treating Psychiatric Disorders: Is it a Psychonaut Legend or a Promising Therapeutic Perspective?

Coppola¹,

Bevione²,

Mondola³

2021

Preprint

View full text Add to dashboard Cite

Psychedelics extracted by plants have been used in religious, spiritual and mystic practices for millennia. In 1957, Dr. Hofmann have identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although the limitations related to the scientific design of many studies, clinical observations performed during the 1950s and the 1960s have shown a potential therapeutic effect of psilocybin in patients affected by depressive symptoms, anxiety, and conversion disorder. Psilocybin was classed as a schedule I substance in 1970, but the fascination for psychedelics remained almost unchanged over time promoting a new scientific interest starting from the 1990s. Recent studies provided further evidences supporting the suggestive hypothesis of a therapeutic use of psilocybin for treating various psychiatric disorders including: pathological anxiety, mood depressive disorder and addiction.

show abstract

Accidental death involving psilocin from ingesting “magic mushroom”

Cited by 3 publications

References 10 publications

Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Genomic Analysis of Stropharia rugosoannulata Reveals Its Nutritional Strategy and Application Potential in Bioremediation

Psilocybin for Treating Psychiatric Disorders: Is it a Psychonaut Legend or a Promising Therapeutic Perspective?

Contact Info

Product

Resources

About